Co-Targeting IL-6 and CDK4/6 to Prevent TNBC in Women Veterans

Who could benefit from this research

What this research studies

This project focuses on preventing TNBC by simultaneously blocking IL-6 signaling and CDK4/6 activity, which preliminary data suggest may drive resistance to therapy. Researchers plan to use pharmacologic approaches to co-target these pathways and test their effect on tumor prevention and progression. The work centers on women veterans with TNBC, aiming to address a high-need subgroup with historically limited options. If successful, the approach could inform future preventive strategies and improve outcomes for this group.

Why it matters

Where this research is happening

• Baltimore VA Medical Center
  Baltimore, United States Active

Researchers

• Principal investigator: Lin, Jiayuh — Baltimore VA Medical Center
• Study coordinator: Lin, Jiayuh

Related research

Other NIH-funded projects on the same topics.

• Genomic study to understand how genetics and epigenetics shape triple-negative breast cancer in African ancestry

  This study looks at how inherited genes and gene activity affect triple-negative breast cancer in people of African ancestry to better understand why outcomes can be worse.

  NIH research Tuskegee University · Tuskegee Institute, United States · NIH-11621786

• Linking heavy metal exposure to a tougher breast cancer type (TNBC)

  Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

  NIH research University of Louisville · Louisville, United States · NIH-11567535

• Dormancy in Triple-Negative Breast Cancer: How Liver and Skin Metastases Go Quiet or Reactivate

  Researchers will study how dormant cancer cells in liver and skin metastases of triple-negative breast cancer become quiescent or wake up, using organ-on-chip models and single-cell analysis to map chromatin states.

  NIH research Massachusetts Institute of Technology · Cambridge, United States · NIH-11531542

• Rac-enhanced CAR-Macrophages against TNBC

  A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

  NIH research University of Louisville · Louisville, United States · NIH-11520503

• A new peptide therapy to help treat metastatic triple-negative breast cancer

  A new peptide therapy called PEG-FUD is being tested to help treat metastatic triple-negative breast cancer by normalizing the tumor environment to improve treatment delivery.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11453153

• Photoacoustic imaging to tailor antibody-drug therapy for TNBC

  A non-invasive imaging approach using light-based sound waves (photoacoustic imaging) is being developed to guide and personalize antibody-drug conjugate therapy for women with triple-negative breast cancer.

  NIH research University of Tx Md Anderson Can Ctr · Houston, United States · NIH-11445261

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.